Web Results


Schwarz Pharma AG war ein börsennotiertes Pharmaunternehmen mit Sitz in Monheim am Rhein und ist seit 2007 Bestandteil des belgischen UCB-Konzerns. 2005 beschäftigte das Unternehmen weltweit 4.100 Mitarbeiter, davon 1.696 in Deutschland, und erzielte einen Umsatz von 991 Millionen Euro. Im Jahr 2007 kam ...


Schwarz Pharma AG manufactures pharmaceuticals products. The Company provides medicines and solutions for cardiovascular, epilepsy, urological, central nervous system, and parkinsons and gastrointestinal diseases. Schwarz Pharma markets its products worldwide.


UAE Drug Regulator Orders Recall Of Schwarz Pharma Heart Drug. The United Arab Emirates ordered a recall of Germany-based Schwarz Pharma's Nitrocine ( glyceryl trinitrate) for treating heart and blood-pressure problems on grounds it may contain impurities. BioPharmaceutical Middle East and Africa. Bookmark.


Schwarz Pharma develops pharmaceutical products.


Schwarz Pharma Mfg., Inc. company profile on Contract Pharma.


Apr 28, 2017 ... In the early years of the 21st century, UCB began to transform into a pure biopharma company. Significant milestones included the acquisition of Celltech, a British biotech firm in 2004, and then German pharma company, Schwarz Pharma, in 2006. At the same time, UCB also filed its first biologic treatment ...


Notice about cookies. This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read ...


Sep 25, 2006 ... LONDON (MarketWatch) -- Belgium's UCB on Monday said it agreed to pay $5.6 billion for Germany's Schwarz Pharma, the third multibillion-dollar takeover in the European pharmaceutical industry in the past five days. UCB (000373953) said it's paying 4.4 billion euros in cash and shares, representing a ...


Sep 25, 2006 ... UCB, the Belgian drugmaker, was on Monday the latest company to join in the rash of mergers among Europe's medium-sized pharmaceutical groups, with an agreed €4.4bn ($5.6bn) cash-and-shares offer for Schwarz Pharma.